Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States

D J Hillebrand, B A Runyon, W G Yasmineh, G P Rynders – 1 December 1996 – Tuberculous peritonitis, although common in Third World countries, remains an uncommon cause of ascites in the United States. Ascitic fluid adenosine deaminase (ADA) activity has been proposed as a useful diagnostic test. The aim of this retrospective study was to determine the clinical utility of ascitic fluid ADA activity in diagnosing tuberculous peritonitis in a U.S. patient population.

Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio

A Robert, O Chazouilleres – 1 December 1996 – Prothrombin time (PT) is a universal indicator of liver disease severity. However, variability in thromboplastin reagents leads to large interlaboratory differences in PT results. The aim of this study was to determine whether the use of the international normalized ratio (INR) or other modes of expression might achieve PT standardization in patients with liver failure.

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

N A Terrault, S Zhou, C Combs, J A Hahn, J R Lake, J P Roberts, N L Ascher, T L Wright – 1 December 1996 – Prophylactic hepatitis B immunoglobulin (HBIg) reduces the risk of reinfection in hepatitis B surface antigen (HBsAg)‐positive liver transplant recipients. In the medical center of this study, high‐dose HBIg immunoprophylaxis is administered at a fixed dose of 10,000 IU monthly, and in this study, the long‐term efficacy of this treatment regimen was examined.

Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: A randomized trial

P Sauer, L Theilmann, S Herrmann, T Bruckner, T Roeren, G Richter, W Stremmel, A Stiehl – 1 December 1996 – Development of stenosis or occlusion of the transjugular intrahepatic portosystemic stent shunt (TIPSS) is one of the major limiting factors in the long‐term viability of this procedure. The efficacy of anticoagulation with heparin which is used in different centers is still unclear.

The creatinine approach to estimate skeletal muscle mass in patients with cirrhosis

M Pirlich, O Selberg, K Boker, M Schwarze, M J Muller – 1 December 1996 – The creatinine‐method to estimate muscle mass is frequently used in clinical studies, although the validity of this approach is uncertain in patients with cirrhosis. In this study 102 patients with cirrhosis differing in cause, clinical state, liver, and renal function were investigated to determine whether reduced liver or renal function may explain in part the low levels of urinary creatinine excretion frequently observed in these patients.

Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation

J S McMillan, D S Bowden, P W Angus, G W McCaughan, S A Locarnini – 1 December 1996 – Recurrent hepatitis B virus (HBV) infection is a major problem in patients undergoing liver transplantation. Previously, we reported that infection with HBV strains containing a mutation in the precore region (G‐to‐A at nucleotide 1896) was associated with severe recurrent disease posttransplantation. In this study we investigated other mutations in the precore/core gene and core promoter which may be associated with this severe recurrence.

Evidence that the HLA DQA1*03 allele confers protection from chronic HCV‐infection in Northern European Caucasoids

C Tibbs, P Donaldson, J Underhill, L Thomson, K Manabe, R Williams – 1 December 1996 – In the search for factors which may influence susceptibility to and outcome from chronic hepatitis C virus (HCV) infection, few studies have considered the influence of host genes. In the present investigation we have performed HLA DRB1, DQA1, DQB1, and DPB1 genotyping on 104 northern European patients with chronic HCV infection and 177 racially and geographically matched controls.

Liver transplantation in HBsAg‐positive HBV‐DNA—negative cirrhotics: Immunoprophylaxis and long‐term outcome

Gian Luca Grazi, Alighieri Mazziotti, Claudia Sama, Elio Jovine, Francesco Stefanini, Rolando Paladini, Roberto Rossi, Antonino Cavallari – 1 November 1996 – The presence of a positive hepatitis B surface antigen (HBsAg) has been considered a highly questionable indication for orthotopic liver transplantation. We report our experience in the treatment of HBsAg‐positive HBV‐DNA—negative cirrhotics with liver transplantation, whether or not followed by passive prophylaxis with specific immunoglobulins.

Subscribe to